Bellerophon, FDA Agree on Design of Phase 3 INOpulse Trial

Bellerophon, FDA Agree on Design of Phase 3 INOpulse Trial
5
(3)

The U.S. Food and Drug Administration (FDA) and Bellerophon Therapeutics agreed on the design of Bellerophon’s Phase 3 trial to test INOpulse — inhaled nitric oxide — in people with pulmonary fibrosis (PF) who are at risk for pulmonary hypertension (PH), the company said.

INOpulse is a device that delivers nitric oxide (NO) in a form that can be inhaled. NO is a potent vasodilator, a compound that causes blood vessels to widen, lowering blood pressure and allowing more blood to flow. This is the rationale behind its therapeutic use in PH, which is defined by abnormally high blood pressure in the vessels of the lung.

With the conclusion of end-of-Phase 2 meetings, Bellerophon and the FDA agreed that the trial will test INOpulse delivered at a dose of 45 mcg/kg ideal body weight/per hour, and the study’s main goal will be the ability of NO to improve moderate to vigorous physical activity (MVPA) of PF patients at risk for PH.

These parameters are the same as those being used in the ongoing Phase 2/3 iNO-PF (NCT03267108) study for a group of 44 participants randomly assigned to receive INOpulse at 45 mcg/kg or a placebo for four months.

Topline results from the iNO-PF trial showed that patients treated with active NO had statistically significant improvements in MVPA, a parameter that includes walking, climbing stairs, and yard work. The increase of 14 minutes per day in MVPA observed corresponds to a 20% improvement compared with the placebo group.

Moreover, researchers saw significant improvements on the St. George’s Respiratory Questionnaire (SGRQ), which measures the impact of respiratory disease on daily life. On average, the total SGRQ score of patients treated with INOpulse dropped by three points. (Higher scores indicate a lower quality of life). A five-point improvement in the shortness of breath measure on the University of California, San Diego Shortness of Breath Questionnaire was also observed.

“We are very pleased with the alignment reached with the FDA on the design of our pivotal Phase 3 trial, which allows us to move confidently towards the initiation of this important study,” Fabian Tenenbaum, CEO of Bellerophon, said in a press release.

“INOpulse, with its targeted pulmonary vasodilation, would potentially become the first therapy to treat a broad PH-PF population that includes patients at low, intermediate, and high risk of pulmonary hypertension. We look forward to initiating our pivotal Phase 3 study in PH-PF shortly,” Tenenbaum said.

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Total Posts: 110
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • antifibrotic therapy
  • IPF symptoms, diagnosis
  • mortality risk, CT scans
  • NP-120 (ifenprodil) trial

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 3

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?